Somatostatin inhibits insulin and glucagon secretion. Insulin and glucagon influence blood sugar levels. These regulatory enzymes are regulated by insulin and glucagon signaling pathways. Somatostatin acts as an inhibitor of both insulin and glucagon. Dipeptidyl peptidase-4 inhibitors inhibit dipeptidyl peptidase-4 and thus reduce glucagon and blood glucose levels. The pancreas is the organ responsible for the secretion of the hormones insulin and glucagon. The basic functions of insulin and glucagon are to maintain glucose homeostasis. These metabolic activities are regulated by several hormones (e.g., insulin, glucagon and epinephrine). It works by increasing insulin release from the pancreas and decreases excessive glucagon release. Others believe deficiencies in glucagon secretion might lead to reactive hypoglycemia. Additionally, gastrin, insulin, cholecystokinin, glucagon, and secretin have been reported to disrupt the MMC. Type 2 diabetes is marked by excess glucagon and insulin resistance from the body. Both glucagon and epinephrine cause high levels of cAMP in the liver. Onset of type 1 diabetes is followed by an increase in glucagon secretion after meals. Glucagon, adrenocorticotropic hormone, and ATP encourage gluconeogenesis.